PGT has a 99% accuracy in predicting an embryo’s sex.
PGT-A (Preimplantation Genetic Testing for Aneuploidy) also known as PGS (Preimplantation Genetic Screening) is a genetic test that screens all 23 pairs of human chromosomes as well as select for gender. PGT–M (Preimplantation Genetic Testing for Monogenic/Single Gene Defects) also known as PGD (Preimplantation Genetic Diagnosis) is designed to help patients who have known genetic abnormalities in their family line. This type of testing is commonly recommended for individuals and couples in which one or both partners have a high risk of passing on a genetic defect.
With 99 % accuracy in predicting an embryo’s sex, PGT-A/PGT-M gives couples the best odds in determining their baby’s sex.
PGT-A and PGT-M
PGT-A allows couples to choose their baby’s sex by identifying male and female embryos conceived in a laboratory, prior to transfer to the woman’s uterus. PGT-A requires a minor surgical procedure to remove eggs from the woman’s ovaries along with IVF fertilization in a lab. After fertilization, specialists examine the embryo for its sex chromosomes (XX for female; XY for male), and then implant an embryo of the selected sex into the woman’s uterus.
PGT-A can help couples not only select the sex of their child, but also determine if an embryo contains the normal number of chromosomes in humans. PGT-A can also improve the implantation rates of embryos transferred by screening them beforehand to determine if there is the correct number of chromosomes (46, XX for female and 46, XY for male).
PGT-M is used prior to implantation to help identify genetic defects within embryos, serving to prevent certain genetic diseases or disorders from being passed on to the child. PGT-M can detect single gene defect disorders that can results in such diseases as muscular dystrophy, sickle cell anemia, cystic fibrosis and Tay-Sachs.